In a significant leap forward for artificial intelligence (AI) in life sciences, Deepcell, a leading company in AI-powered single cell analysis, has announced the achievement of crucial commercial milestones for its REM-I platform. This development marks a pivotal moment for the company, as it prepares to share its vision for the future of generative AI in single cell analysis at the upcoming 42nd annual J.P. Morgan Healthcare Conference.
A Year of Remarkable Progress
Deepcell’s journey over the past year has been nothing short of extraordinary. According to Maddison Masaeli, Ph.D., Cofounder and CEO of Deepcell, “We launched the REM-I platform, completed technology evaluations across seven sites, launched the Spark program, and began operationalizing manufacturing. We’ve also placed our first commercial unit for field testing and secured orders from university research facilities, academic medical centers, and biopharma companies across three continents.”
REM-I: A New Frontier in Alzheimer’s Research
The REM-I platform’s first installation at an academic institution is poised to make significant contributions to Alzheimer’s disease research. The platform’s potential to identify differential cell states in Alzheimer’s disease using the Deepcell Human Foundation Model is a groundbreaking development in the field.
Global Reach and Diverse Applications
Deepcell has not only made direct sales in the United States and Western Europe but has also established a global network of distributors, expanding its reach into Asia and the Middle East. Marc Montserrat, Chief Business Officer at Deepcell, highlights the significance of their first orders, “It demonstrates the growing awareness of the importance of morpholomics in understanding cell biology.”
Collaborative Efforts with NVIDIA
Deepcell’s recent announcement of a collaboration with NVIDIA is set to accelerate the development and adoption of advanced computer vision solutions in life sciences. Mahyar Salek, Ph.D., Cofounder, President, and CTO of Deepcell, expressed excitement about the possibilities of incorporating multimodal and generative AI into their platform. “Our partnership with NVIDIA will help us bring these advancements to our customers, enabling new discoveries at an unprecedented speed,” said Salek.
The REM-I Platform: A Paradigm Shift
The REM-I platform is a high-dimensional cell morphology analysis and sorting platform, which is fundamentally different from traditional microscopy and flow cytometry methods. By integrating high-resolution imaging of single cells and label-free sorting with AI, the REM-I platform offers a new, quantitative approach to understand and analyze cell morphology.
Deepcell’s Vision: Unbounded Discovery
Deepcell, a spin-off from Stanford University, has been a game-changer in the life sciences sector. With nearly $100 million in venture capital, the company has been at the forefront of integrating AI in cell biology, creating new avenues for research and potential applications in diagnostic testing and therapeutics.
Looking Ahead
As Deepcell prepares for the full commercialization of the REM-I platform in 2024, the life sciences community eagerly anticipates the new doors this technology will open in various fields, from cancer biology to stem cell research.
For more information, visit Deepcell’s website.
